PDL Biopharma, Biogen say early data from volociximab trials show antitumor activity

By Elaine Rigoli

Tampa, Fla., June 6 - PDL BioPharma, Inc. and Biogen Idec said interim results on volociximab (M200) show it may inhibit tumor angiogenesis regardless of the pro-angiogenic growth factors that promote tumor growth.

This could potentially improve the clinical outcome of patients with different types of advanced cancers that may be fueled by a variety of angiogenic stimuli, officials said.

Data was evaluated from three phase 2 open-label clinical trials of volociximab 10 mg/kg administered intravenously every two weeks as either a single agent or in combination with chemotherapy as part of the treatment regimens for metastatic renal cell carcinoma, adenocarcinoma of the pancreas and melanoma.

"We are encouraged by the early signs of tolerability suggested by these exploratory trials. We look forward to advancing the volociximab clinical development program with our partner, Biogen Idec, with additional phase 2 studies of volociximab at higher doses, including an early trial in patients with melanoma to further characterize tumor expression of alpha5-beta1," said Steven Benner, PDL's senior vice president and chief medical officer, in a news release.

PDL BioPharma is a biopharmaceutical company based in Fremont, Calif.

Biogen is a biopharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.